Abstracts tagged "Epidemiology"

Abstract Number: 1904 • ACR Convergence 2024
Evaluation of the Economic Burden of Psoriatic Arthritis: Assessment of Direct Costs Using National Administrative Databases at National Level
Wilson Bautista-Molano¹, Ingrid Ramirez-bolivar², Cristina Pinilla-Forero³ and Luz A Ruiz⁴, ¹University Hospital Fundación Santa Fe de Bogotá, Bogotá, Colombia, ²Janssen, Bogotá, Colombia, ³Janssen, Bogotá, ⁴CODENTMED, Bogotá, Colombia
Background/Purpose: Psoriatic arthritis (PsA) is a high-cost disease due to its significant impact on patients' quality of life and the extensive resources required for its…
Abstract Number: 2312 • ACR Convergence 2024
National Prevalence of Psoriatic Arthritis in the United States: Data from National Health and Nutrition Examination Survey [NHANES]
Dilli Poudel¹, Rashmi Dhital² and Paras Karmacharya³, ¹Vanderbilt University, Nashville, TN, Brentwood, TN, ²UC San Diego, Brentwood, TN, ³Vanderbilt University, Nashville, TN, Hermitage, TN
Background/Purpose: Psoriatic arthritis (PsA) is a chronic inflammatory disease which significantly impacts quality of life and healthcare costs. However, true US population-level prevalence data is…
Abstract Number: 2554 • ACR Convergence 2024
Prevalence and Clinical Characteristics of Vasculitis in the Alaska Native and American Indian Peoples of Alaska
Ben Henderson¹, Vivek Mehta², Peter Holck², Tammy Choromanski², Amy Wilson², Flora Lee² and Elizabeth Ferucci², ¹University of Washington School of Medicine, Seattle, WA, ²Alaska Native Tribal Health Consortium, Anchorage, AK
Background/Purpose: The objective of this study was to determine the prevalence and clinical characteristics of vasculitis in Alaska Native and American Indian (AN/AI) peoples of…
Abstract Number: 0145 • ACR Convergence 2024
Community Mobility in a Diverse Cohort of Individuals with Systemic Lupus Erythematosus
Leila Milanfar¹, Jinoos Yazdany², Amanda Eudy³, Courtney Hoge⁴, Charmayne M. Dunlop-Thomas⁵, Patti Katz⁶ and Laura Plantinga⁷, ¹University of California San Francisco, San Francisco, CA, ²UCSF, San Francisco, CA, ³Duke University, Raleigh, NC, ⁴Emory University, Atlanta, GA, ⁵Emory University School of Medicine, Department of Medicine, Division of Rheumatology, Atlanta, GA, ⁶UCSF, San Rafael, CA, ⁷University of California, San Francisco, San Francisco, CA
Background/Purpose: Measurement of the extent to which individuals move throughout their community and participate in social activities (“community mobility”) can provide a snapshot of how…
Abstract Number: 0280 • ACR Convergence 2024
Trends in Management and Consultations for Gout: A Study of 18 Million Adults Using the OpenSAFELY Platform
Mark Russell¹, Jon Massey², Edward Roddy³, Brian MacKenna⁴, Seb Bacon⁴, Ben Goldacre⁴, Colm Andrews⁴, George Hickman⁴, Amir Mehrkar², Arti Mahto⁵, Andrew Rutherford⁶, Samir Patel¹, Maryam Adas⁷, Edward Alveyn⁷, deepak Nagra¹, Katie Bechman⁷, Joanna Ledingham⁸, Joanna Hudson⁹, Sam Norton¹, Andrew Cope⁷ and James Galloway¹⁰, ¹King's College London, London, England, United Kingdom, ²University of Oxford, Oxford, England, United Kingdom, ³Keele University, Keele, England, United Kingdom, ⁴University of Oxford, Oxford, United Kingdom, ⁵King's College Hospital NHS Foundation Trust, London, United Kingdom, ⁶King's College Hospital NHS Foundation Trust, London, England, United Kingdom, ⁷King's College London, London, United Kingdom, ⁸Portsmouth Hospitals University NHS Trust, Portsmouth, United Kingdom, ⁹King's College London, King's College London, United Kingdom, ¹⁰Centre for Rheumatic Diseases, King's College London, London, United Kingdom
Background/Purpose: Data from before the COVID-19 pandemic had shown persistently poor care for people with gout in many countries worldwide. Whether this was further exacerbated…
Abstract Number: 0503 • ACR Convergence 2024
Use of Janus Kinase Inhibitors Before and After European Medicines Agency Safety Recommendations
Patrick-Pascal Strunz¹, Linus Maximilian Risser², Matthias Englbrecht³, Torsten Witte⁴, Matthias Froehlich⁵, Marc Schmalzing⁶, Michael Gernert⁷, Peter Bartz-Bazzanella⁸, Sebastian Hueper⁹, Cay von Der Decken¹⁰, Georg Gauler¹¹, Susanna Spaethling-Mestekemper¹², Christoph Kuhn¹³, Kirsten Karberg¹⁴, Wolfgang Vorbrueggen¹⁵, Martin Welcker¹⁶ and Stefan Kleinert¹⁷, ¹University hospital of Wuerzburg, Wuerzburg, Germany, ²Hannover Medical School, Hannover, Germany, ³Freelance Healthcare Data Scientist, Eckental, ⁴Dept of Immunology and Rheumatology, Hannover, Germany, ⁵Uniklinikum Wuerzburg, Medizinische Klinik II, Wuerzburg, Germany, ⁶University Hospital Wuerzburg, Würzburg, Germany, ⁷Medicine II, Division Rheumatology/Clinical Immunology, University Hospital of Wuerzburg, Wuerzburg, ⁸Rhein-Maas Klinikum, Wuerselen, Germany, ⁹Praxis für Rheumatologie und Osteologie, Hildesheim, Germany, ¹⁰Klinik für Internistische Rheumatologie, Rhein-Maas-Klinik Wuerselen, Würselen, ¹¹rheumapraxis, Osnabrück, Germany, ¹²Rheumapraxis Muenchen, Muenchen, Germany, ¹³Praxis für Rheumatologie, Karlsruhe, Germany, ¹⁴Rheumatologisches Versorgungszentrum Steglitz, Berlin, Germany, ¹⁵RheumaDatenRhePort GbR, Wuerselen, Germany, ¹⁶Medizinisches Versorgungszentrum für Rheumatologie Dr. M. Welcker GmbH, Planegg, Germany, ¹⁷Praxisgemeinschaft Rheumatologie - Nephrologie (PGRN), Erlangen, Germany
Background/Purpose: Safety recommendations for Janus kinase inhibitors (JAKi) issued by the European Medical Agency (EMA) in 2023 could potentially influence prescription patterns for drugs used…
Abstract Number: 0977 • ACR Convergence 2024
Vaccine Effectiveness and Safety of Recombinant Zoster Vaccine (RZV) in Rheumatoid Arthritis (RA) Patient Populations Aged 50 Years and Older
Emily Rayens¹, Lina Sy¹, Lei Qian¹, Jun Wu¹, Bradley Ackerson¹, Yi Luo¹, Yanjun Cheng¹, Antony Lin¹, Zendi Solano¹, Justine De Jesus¹, Britta Amundsen¹, Ana Florea¹, Jen Ku¹, Elizabeth Chmielewski-Yee², Driss Oraichi², Harry Seifert², Huifeng Yun² and Hung-Fu Tseng¹, ¹Kaiser Permanente Southern California, Pasadena, CA, ²GSK, Rockville, MD
Background/Purpose: Individuals with rheumatoid arthritis (RA) are at higher risk of herpes zoster (HZ) compared to the general population. This interim analysis evaluated the vaccine…
Abstract Number: 1007 • ACR Convergence 2024
Demographic, Social, and Disease Factors Associated with Interstitial Lung Disease and Disease-Related Death in Dermatomyositis
Connor Buechler, Lindsey Wanberg, Nawang Singhe, Cody Rasner, Joseph McGrath, Ziou Jiang, Karen Baker-James and David Pearson, University of Minnesota, Minneapolis, MN
Background/Purpose: Dermatomyositis (DM) is associated with significant morbidity and mortality due to disease-related progressive interstitial lung disease (ILD) and malignancy. However, little is known about…
Abstract Number: 1201 • ACR Convergence 2024
Association of COVID-19 Vaccinations with Osteoarthritis Flares: A Case-Crossover Study
Minerva Nong¹, Colby Lewis V², Genna Braverman³, Vivian Bykerk³, Nathaniel Hupert², Medha Barbhaiya³ and Lisa Mandl³, ¹Hospital for Special Surgery, Tampa, FL, ²Weill Cornell Medicine, New York, NY, ³Hospital for Special Surgery, New York, NY
Background/Purpose: People with osteoarthritis (OA) commonly experience periods of increased pain and stiffness (“flares”), which can be distressing and disabling. Despite the prevalence of OA…
Abstract Number: 1508 • ACR Convergence 2024
Clinical Characteristics and Prognosis of Late-onset Systemic Lupus Erythematosus in 305 Japanese Patients
Yuko Shirota¹, Misa Oguma², Ryo Kuwata³, Yumi Tajima⁴, Yumiko Oka⁵, Miki Takeshita², Takao Kodera² and Tomonori Ishii², ¹Tohoku University Hospital / Department of Hematology and Rheumatology, Sendai, Japan, ²Tohoku Medical and Pharmaceutical University / Department of Hematology and Rheumatology, Sendai, Japan, ³National Center for Global Health and Medicine / Division of Rheumatic Diseases, Shinjyuku, Tokyo, Japan, ⁴Tohoku Medical and Pharmaceutical University / Department of Hematology and Rheumatology, Sendai, Miyazaki, Japan, ⁵Tohoku Medical and Pharmaceutical University / Department of Hematology and Rheumatology, Sendai
Background/Purpose: In recent years, the number of older patients with systemic lupus erythematosus (SLE) in Japan has been increasing, with particular attention to those developing…
Abstract Number: 1881 • ACR Convergence 2024
Cross-State Comparative Assessment of Burden of Rheumatoid Arthritis in the United States and It’s Trend from 1990-2021: A Benchmarking Analysis for the Global Burden of Disease Study 2022
Rafael Sanchez-Dopazo,¹, Eva Kalra², Shadi Abuhashem³, abobakr Saleh⁴, Khalid Faris⁵, Rutvik Raval⁶, Shamitha Hejmadi⁶, Lovekumar Vala⁷, Riya Dhadhal⁸ and Hardik Desai⁹, ¹Larkin Community Hospital Palm Springs Campus, Hialeah, FL, ²Trident Medical Cente, Charleston, SC, ³Alquds University, Jerusalem, West Bank, Palestine, 9458123, Gaza, Palestinian Territories, ⁴kasr alainy Medical School - Cairo University,Egypt/ 11956, Cairo, Egypt, ⁵Studied in Al-Quds university, Palestine, Gaza, Palestinian Territories, ⁶B.J. Medical College, Ahmedabad, India, ⁷Department of Internal Medicine, Shantabaa Medical College and General Hospital, Amreli, Gujarat, India, 365601, Amreli, Gujarat, India, ⁸SMIMER Hospital & Medical College, Surat, Gujarat, India, ⁹Gujarat Adani Institute of Medical Sciences, Bhuj, India
Background/Purpose: The burden of Rheumatoid Arthritis (RA) in the United States is considerable, both in terms of its prevalence and the economic costs it incurs.…
Abstract Number: 1906 • ACR Convergence 2024
Bayesian Algorithm to Identify Osteoarthritis in Administrative Health Data Without Requiring Chart Review
S. Reza Jafarzadeh¹, Sarah Tilley¹, Anup Arvind¹ and David Felson², ¹Boston University Chobanian & Avedisian School of Medicine, Boston, MA, ²Boston University, Boston, MA
Background/Purpose: Osteoarthritis (OA) is the most prevalent arthritis and a significant contributor to Years Lived with Disability. Administrative health data are widely used to study…
Abstract Number: 2322 • ACR Convergence 2024
Predictors of Work Impairment and Absence Amongst People with Psoriatic Arthritis (PsA) – Evidence from the British Society for Rheumatology PsA Register (BSR-PsA)
Lili Xu¹, Gareth Jones¹, Ovidiu Rotariu¹, Philip S. Helliwell², Stefan Siebert³, Rosemary Hollick¹ and Gary Macfarlane¹, ¹University of Aberdeen, Aberdeen, United Kingdom, ²Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK, Leeds, United Kingdom, ³School of Infection and Immunity, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, United Kingdom
Background/Purpose: People with PsA often report that their condition affects their ability to work. Poor work outcomes, such as work impairment, absence or leaving work,…
Abstract Number: 2556 • ACR Convergence 2024
A Multi-center Study of Associations Between Neighborhood-Level Child Opportunity, Initial Disease Severity and Acute Care Utilization Among Children with SLE
Joyce Chang¹, Jessica Liu¹, Emily Smitherman², Pooja Patel³, Gabrielle Alonzi¹, Gabrielle Morgan⁴, Livie Timmerman⁵, Laura Berbert⁶, Edie Weller¹, Karen Costenbader⁷ and Mary Beth Son⁸, ¹Boston Children's Hospital, Boston, MA, ²University of Alabama at Birmingham, Birmingham, AL, ³Ann and Robert H. Lurie Children's Hospital of Chicago, Chicago, IL, ⁴Ann & Robert H. Lurie Children's Hospital of Chicago and Northwestern University Feinberg School of Medicine, Chicago, IL, ⁵University of Alabama at Birmingham, Gardendale, AL, ⁶Boston Children's Hospital, Belmont, MA, ⁷Brigham and Women's Hospital/ Harvard Medical School, Boston, MA, ⁸Boston Children's Hospital, Brookline, MA
Background/Purpose: Child opportunity is defined as the neighborhood resources and conditions that promote healthy childhood development. We determined whether low neighborhood-level opportunity associates with more…
Abstract Number: 0147 • ACR Convergence 2024
Clinical Characteristics and Biomarkers Associated with Detectable High-Sensitivity Cardiac Troponin in Patients with Rheumatoid Arthritis
Ilana Usiskin¹, Mary Jeffway¹, Feng Liu¹, Nancy Shadick¹, Michael Weinblatt², Brittany Weber³ and Katherine Liao¹, ¹Brigham and Women's Hospital, Boston, MA, ²Brigham and Women's Hospital/ Harvard Medical School, Waban, MA, ³Brigham and Women's Hospital, DEDHAM, MA
Background/Purpose: General population-based cardiovascular (CV) risk estimators are known to underestimate CV risk in RA. High-sensitivity cardiac troponin T (hs-cTnT), typically measured during a work-up…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].